Why HighFive™

HighFive cells (sometimes referred to as High-Five or Hi5) represent a safe, effective and inexpensive platform for protein production.

Indeed, their remarkable ability to produce very large amounts of recombinant proteins – such as diagnostic reagents and recombinant vaccines – remains unmatched.

The HighFive cells were originaly isolated from insects in BTI’s Granados lab in the late 1980’s.

Virus-free sub-clones of the original HighFive cells can be obtained from BTI or commercial partners for testing for non-commercial use, and affordable and flexible commercial licenses can be obtained from BTI.

A tested platform for protein production

  • Hundreds of labs around the world use these cells.
  • HighFive cell lines were used to produce an FDA-approved human vaccine. Additional human and animal vaccines expressed in HighFive cells or virus-free sub-clones are currently at various stages of the regulatory approval process.

Safety first

  • HighFive cells are not known to potentially host any human pathogens.

Virus-free sub-clones

  • The original HighFive cells were found to host a non-pathogenic nodavirus. BTI researchers have developed several sub-clones that are virus-free and available for licensing.

True scalability with unmatched yields

  • The baculovirus expression vector system (BEVS) in insect cells offers highly scalable and inexpensive protein production. HighFive cells and sub-clones have been reported to produce 2-10x high levels of recombinant proteins compared to Sf9/Sf21 insect cells.

Proteins with less contaminants

  • When considering BEVS for protein expression, Sf9/Sf21 produce very high titers of baculoviruses. That can represent a major drawback during protein purification. Purifying proteins produced in HighFive cells is preferable, with as much as 100-fold less baculovirus produced.

Affordable licensing with peace of mind

  • BTI is the sole proprietor of HighFive cells and related sub-clones.


For licensing inquires contact licensing@btiscience.org

Headshot of Julien Fey

Julien Fey

Director of Technology Transfer


Headshot of Kelli Monce

Kelli Monce

Technology Transfer Specialist


Headshot of Paul Debbie

Paul Debbie

Director of Research, Director of New Business Development


Subscribe to BTI's LabNotes Newsletter!



Boyce Thompson Institute
533 Tower Rd.
Ithaca, NY 14853

Copyright © 2023 | Boyce Thompson Institute | All rights reserved | Privacy Policy | Cookie Policy